http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-113754-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_05a203d85ee01909eaf728dc16f0f6cb |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D498-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-439 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate | 2018-10-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_594483949aff0f08103e8ab1e51a86bb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_00debe66d31b776621cc151353f57a29 |
| publicationDate | 2020-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-113754-A1 |
| titleOfInvention | CRYSTAL FORM OF LORLATINIB HYDRATE FREE BASE |
| abstract | Claim 1: A crystalline form of (10R) -7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4- ( methene) pyrazolo [4,3-h] [2,5,11] benzoxadiazacyclotetradecin-3-carbonitrile (lorlatinib) free base, with a powder X-ray diffraction pattern (PXRD) characterized by comprising peaks at 2q values of: 8.8, 17.6 and 18.8 ° 2q ± 0.2 ° 2q. |
| priorityDate | 2017-10-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 18.